Drug, across the briefings
Buparlisib across 18 cancers
Buparlisib appears in 18 of the briefings; no FDA label names any of them.
| Disease | FDA label | Open Targets stage, on which gene | Trials | Active |
|---|---|---|---|---|
| Anal cancer | phase 3 on PIK3CA | — | — | |
| Bladder cancer | phase 3 on PIK3CA | — | — | |
| Breast cancer | phase 3 on PIK3CA | 27 | 0 | |
| Cervical cancer | phase 3 on PIK3CA | 2 | 0 | |
| Chronic lymphocytic leukemia | phase 3 on PIK3CD | 2 | 0 | |
| Colorectal cancer | phase 3 on PIK3CA | 6 | 0 | |
| Endometrial cancer | phase 3 on PIK3CA | 4 | 0 | |
| Follicular lymphoma | phase 3 on PIK3CD | 4 | 0 | |
| Gallbladder cancer | phase 3 on PIK3CA | — | — | |
| Gastric cancer | phase 3 on PIK3CA | 1 | 0 | |
| Glioblastoma | phase 3 on PIK3CA | 6 | 0 | |
| Head and neck cancer | phase 3 on PIK3CA | 7 | 0 | |
| Lower-grade glioma | phase 3 on PIK3CA | — | — | |
| Merkel cell carcinoma | phase 3 on PIK3CA | — | — | |
| Nasopharyngeal carcinoma | phase 3 on PIK3CA | — | — | |
| Ovarian cancer | phase 3 on PIK3CA | 4 | 0 | |
| Thyroid cancer | phase 3 on PIK3CA | 1 | 0 | |
| Vulvar cancer | phase 3 on PIK3CA | — | — |
The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.